Wall Street Is Ignoring a Key Truth About GLP-1s: Many Patients Quit

Wall Street has fallen hard for GLP-1s. Stocks tied to weight loss and diabetes drugs like Ozempic, Wegovy, and Mounjaro are flying high. Analysts are predicting a multi-hundred-billion-dollar market. Pharma companies are riding a wave of investor enthusiasm. But in all the financial euphoria, one inconvenient truth keeps getting buried: a significant number of patients who start GLP-1 therapy end up discontinuing due to side effects.

That’s not just a medical footnote. It’s a reality with significant implications for long-term sales, patient outcomes, and the sustainability of this supposed blockbuster category.

The Dropout Problem

Clinical trial data and real-world studies have consistently shown that 20% to 70% of patients stop taking GLP-1 with the first year, often because of gastrointestinal side effects like nausea, vomiting, diarrhea, and constipation. For some, these side effects are manageable. For others, they’re debilitating. And while physicians can adjust dosages or suggest temporary breaks, many patients ultimately choose to stop.

The percentage of patients who discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy varies by population and indication. Still, real-world data consistently show that approximately 20–54% of patients discontinue GLP-1 therapy within the first year.

In patients with type 2 diabetes, extensive registry studies report 1-year discontinuation rates of 21–32%. For example, a Danish nationwide study found a 12-month discontinuation rate of 21.2%, while a US cardiology clinic cohort reported a 12-month discontinuation rate of 32.2%. A Swedish national registry found a 1-year discontinuation rate of 23.6% and a 3-year rate of 38.5%.

In patients using GLP-1 receptor agonists for obesity or overweight, discontinuation rates are higher. A recent US cohort study of over 125,000 adults found that 53.6% discontinued therapy by 1 year and 72.2% by 2 years, with discontinuation rates significantly higher in those without type 2 diabetes (1-year: 64.8%; 2-year: 84.4%) compared to those with diabetes (1-year: 46.5%; 2-year: 64.1%). The Obesity Society, in its 2025 joint advisory, notes that real-world adherence is much lower than in clinical trials, with only 33–50% of patients remaining on therapy at 1 year and about 15% at 2 years.

In summary, the percentage of patients who discontinue GLP-1 therapy within 1 year ranges from about 20% to over 50%, depending on the indication and population, with higher rates observed in obesity management than in type 2 diabetes

Yet if you only read investor reports or earnings calls, you might believe these drugs are miracle cures that everyone stays on forever. That narrative helps boost stock prices—but it distorts the reality of how human behavior and biology work.

A Misread on Adherence

Wall Street loves recurring revenue. The assumption is that patients who start a GLP-1 will be on it indefinitely, creating a “lifetime customer” model similar to insulin or statins. But GLP-1s aren’t just pills you pop once a day with no side effects. They’re often injectables, expensive, and for many, physically unpleasant.

Assuming perfect adherence is a dangerous fantasy. Long-term sales projections built on that premise could come crashing down if investors suddenly grasp how fragile adherence is.

The Human Side of the Story

Patients aren’t revenue streams. They’re people trying to live healthier lives, often after years of struggling with obesity or type 2 diabetes. When they start GLP-1 therapy, many are hopeful. But when the side effects kick in, that hope turns into frustration. Some feel worse than they did before the drug. Others can’t afford to stay in therapy even if they wanted to, especially without insurance coverage or employer support.

The discontinuation rate isn’t just a statistic. It’s a warning sign that patient-centered care—and reality—aren’t being factored into the market hype.

What This Means for Pharma and Investors

If the GLP-1 category is going to deliver on its promise, companies need to take discontinuation seriously. That means developing better-tolerated drugs, improving patient onboarding and education, and helping doctors manage side effects more effectively. It also means insurers and employers will need to think carefully about how to support patients through the ups and downs of therapy.

For investors, it’s time for a reality check. The GLP-1 market may indeed be big, but it’s not immune to human behavior. If a large percentage of patients drop out, that’s a direct hit to revenue, no matter how promising the drug’s mechanism of action may be.

Bottom Line:

The GLP-1 gold rush is real. But if Wall Street keeps pretending everyone who starts therapy stays on it forever, they’re setting themselves up for disappointment. Patient behavior matters. Side effects matter. And the dropout rate isn’t a rounding error—it’s a red flag.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply